326 related articles for article (PubMed ID: 29116995)
21. Evaluation of an alternative extended-infusion piperacillin-tazobactam dosing strategy for the treatment of gram-negative infections.
Winstead EM; Ratliff PD; Hickson RP; Mueller JE; Judd WR
Int J Clin Pharm; 2016 Oct; 38(5):1087-93. PubMed ID: 27333796
[TBL] [Abstract][Full Text] [Related]
22. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.
Roberts JA; Abdul-Aziz MH; Davis JS; Dulhunty JM; Cotta MO; Myburgh J; Bellomo R; Lipman J
Am J Respir Crit Care Med; 2016 Sep; 194(6):681-91. PubMed ID: 26974879
[TBL] [Abstract][Full Text] [Related]
23. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU: Intermittent versus continuous infusion. A retrospective cohort study.
Dhaese SAM; De Kezel M; Callant M; Boelens J; De Bus L; Depuydt P; De Waele JJ
J Crit Care; 2018 Oct; 47():164-168. PubMed ID: 30005302
[TBL] [Abstract][Full Text] [Related]
24. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience.
Richter DC; Frey O; Röhr A; Roberts JA; Köberer A; Fuchs T; Papadimas N; Heinzel-Gutenbrunner M; Brenner T; Lichtenstern C; Weigand MA; Brinkmann A
Infection; 2019 Dec; 47(6):1001-1011. PubMed ID: 31473974
[TBL] [Abstract][Full Text] [Related]
25. Outcomes of extended-infusion piperacillin-tazobactam: a retrospective analysis of critically ill patients.
Lee GC; Liou H; Yee R; Quan CF; Neldner K
Clin Ther; 2012 Dec; 34(12):2297-300. PubMed ID: 23195962
[TBL] [Abstract][Full Text] [Related]
26. Continuous infusion of piperacillin/tazobactam in septic critically ill patients--a multicenter propensity matched analysis.
Gonçalves-Pereira J; Oliveira BS; Janeiro S; Estilita J; Monteiro C; Salgueiro A; Vieira A; Gouveia J; Paulino C; Bento L; Póvoa P
PLoS One; 2012; 7(11):e49845. PubMed ID: 23185458
[TBL] [Abstract][Full Text] [Related]
27. Dose optimization of piperacillin/tazobactam in critically ill children.
De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
[TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
[TBL] [Abstract][Full Text] [Related]
29. Higher than standard dosing regimen are needed to achieve optimal antibiotic exposure in critically ill patients with augmented renal clearance receiving piperacillin-tazobactam administered by continuous infusion.
Carrié C; Legeron R; Petit L; Ollivier J; Cottenceau V; d'Houdain N; Boyer P; Lafitte M; Xuereb F; Sztark F; Breilh D; Biais M
J Crit Care; 2018 Dec; 48():66-71. PubMed ID: 30172963
[TBL] [Abstract][Full Text] [Related]
30. Continuous Infusion of Piperacillin/Tazobactam and Meropenem in ICU Patients Without Renal Dysfunction: Are Patients at Risk of Underexposure?
Esteve-Pitarch E; Gumucio-Sanguino VD; Cobo-Sacristán S; Shaw E; Maisterra-Santos K; Sabater-Riera J; Pérez-Fernandez XL; Rigo-Bonnin R; Tubau-Quintano F; Carratalà J; Colom-Codina H; Padullés-Zamora A
Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):527-538. PubMed ID: 34131869
[TBL] [Abstract][Full Text] [Related]
31. Increased Risk of Acute Kidney Injury in Critically Ill Children Treated With Vancomycin and Piperacillin/Tazobactam.
Holsen MR; Meaney CJ; Hassinger AB; Fusco NM
Pediatr Crit Care Med; 2017 Dec; 18(12):e585-e591. PubMed ID: 28906422
[TBL] [Abstract][Full Text] [Related]
32. PIPERACILLIN/TAZOBACTAM IN CONTINUOUS INFUSION VERSUS INTERMITTENT INFUSION IN CHILDREN WITH FEBRILE NEUTROPENIA.
Solórzano-Santos F; Quezada-Herrera A; Fuentes-Pacheco Y; Rodríguez-Coello G; Aguirre-Morales CE; Izelo-Flores D; Muñoz-Hernández O; Miranda-Novales MG; Labra-Zamora MG
Rev Invest Clin; 2019; 71(4):283-290. PubMed ID: 31448789
[TBL] [Abstract][Full Text] [Related]
33. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
[TBL] [Abstract][Full Text] [Related]
34. Parameters influencing the pharmacokinetics/pharmacodynamics of piperacillin/tazobactam in patients with febrile neutropenia and haematological malignancy: a prospective study.
Benech N; Dumitrescu O; Conrad A; Balsat M; Paubelle E; Ducastelle-Lepretre S; Labussière-Wallet H; Salles G; Cohen S; Goutelle S; Ader F;
J Antimicrob Chemother; 2019 Sep; 74(9):2676-2680. PubMed ID: 31219562
[TBL] [Abstract][Full Text] [Related]
35. Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
Kim A; Sutherland CA; Kuti JL; Nicolau DP
Pharmacotherapy; 2007 Nov; 27(11):1490-7. PubMed ID: 17963458
[TBL] [Abstract][Full Text] [Related]
36. Results of the effectiveness of two piperacillin-tazobactam molecules in the real world.
Machado-Alba JE; Gaviria-Mendoza A; Machado-Duque ME
Int J Infect Dis; 2018 Nov; 76():91-96. PubMed ID: 30244077
[TBL] [Abstract][Full Text] [Related]
37. Comparative Impact of an Optimized PK/PD Target Attainment of Piperacillin-Tazobactam vs. Meropenem on the Trend over Time of SOFA Score and Inflammatory Biomarkers in Critically Ill Patients Receiving Continuous Infusion Monotherapy for Treating Documented Gram-Negative BSIs and/or VAP.
Gatti M; Rinaldi M; Tonetti T; Siniscalchi A; Viale P; Pea F
Antibiotics (Basel); 2024 Mar; 13(4):. PubMed ID: 38666972
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
[TBL] [Abstract][Full Text] [Related]
39. Comparative Incidence of Acute Kidney Injury in Critically Ill Patients Receiving Vancomycin with Concomitant Piperacillin-Tazobactam or Cefepime: A Retrospective Cohort Study.
Hammond DA; Smith MN; Painter JT; Meena NK; Lusardi K
Pharmacotherapy; 2016 May; 36(5):463-71. PubMed ID: 26952639
[TBL] [Abstract][Full Text] [Related]
40. Comparison of acute renal injury associated with intermittent and extended infusion piperacillin/tazobactam.
McCormick H; Tomaka N; Baggett S; Heierman T; LaFosse J; Gilbert S; Imhof K
Am J Health Syst Pharm; 2015 Jun; 72(11 Suppl 1):S25-30. PubMed ID: 25991590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]